PFNX News and Press, Pfenex Inc. From 11/20/19

SAN DIEGO, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pf ēnex Expression Technology® to develop and improve protein therapies for unmet patient needs. Using the patented Pf ...

SAN DIEGO, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and improve protein therapies for unmet patient needs. Using the patented Pf�...

SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), today announced that Susan Knudson has resigned for personal reasons from her role as Senior Vice President, Chief Financial Officer effective November 13, 2019, but will continue to support the company by provi...

Pfenex, Inc. (PFNX) Q3 2019 Earnings Conference Call November 7, 2019 16:30 ET Company Participants Eef Schimmelpennink - President & CEO Susan Knudson - CFO Conference Call Participants Brandon Folkes - Cantor Fitzgerald & Co. Jason Butler - JMP Securities Andy H...

Image source: The Motley Fool. Pfenex   (NYSEMKT: PFNX) Q3 2019 Earnings Call Nov 07, 2019 , 4:30 p.m. ET Operator Continue reading

Pfenex (NYSEMKT: PFNX ): Q3 GAAP EPS of $0.09 beats by $0.02 . More news on: Pfenex Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Received U.S. FDA approval for PF708 to treat osteoporosis and submitted comparative use human factors (HF) study report to FDA; Commercial launch by Alvogen expected upon FDA decision on the therapeutic equivalence rating relative to Forteo® Announced partnership with Arcellx to...

SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that Eef Schimmelpennink, President and Chief Executive Officer, will be presenting at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20 th , taking place at the Waldorf Hi...

Below are the five companies in the Biotechnology industry with the lowest sales per share. Sales per share is a valuable metric in comparing relative value for companies in the same industry. Actinium Pharmaceuticals Inc. ranks lowest with sales per share of $0.00. Following is Pfenex Inc. w...

Bausch Health Companies (NYSE: BHC ) initiated with Outperform rating and $35 (54% upside) price target at Cowen and Company. More news on: Bausch Health Companies Inc., Illumina, Inc., MannKind Corporation, Healthcare stocks news, Stocks on the move, , Read more ...